Cargando…
Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area
PURPOSE: The purpose of this study was to investigate the effect of neutropenia during the first cycle of induction chemotherapy (IC-1) on survival in locoregionally advanced nasopharyngeal carcinoma (LANPC). MATERIALS AND METHODS: Eligible patients (n=545) with LANPC receiving IC+concurrent chemora...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056978/ https://www.ncbi.nlm.nih.gov/pubmed/28745036 http://dx.doi.org/10.4143/crt.2017.255 |
_version_ | 1783341430540861440 |
---|---|
author | Xu, Cheng Yang, Shi-Ping Zhang, Yuan Tang, Ling-Long Zhou, Guan-Qun Liu, Xu Mao, Yan-Ping Guo, Rui Li, Wen-Fei Chen, Lei Lin, Ai-Hua Sun, Ying Ma, Jun |
author_facet | Xu, Cheng Yang, Shi-Ping Zhang, Yuan Tang, Ling-Long Zhou, Guan-Qun Liu, Xu Mao, Yan-Ping Guo, Rui Li, Wen-Fei Chen, Lei Lin, Ai-Hua Sun, Ying Ma, Jun |
author_sort | Xu, Cheng |
collection | PubMed |
description | PURPOSE: The purpose of this study was to investigate the effect of neutropenia during the first cycle of induction chemotherapy (IC-1) on survival in locoregionally advanced nasopharyngeal carcinoma (LANPC). MATERIALS AND METHODS: Eligible patients (n=545) with LANPC receiving IC+concurrent chemoradiotherapy were included. Based on nadir neutrophil afterIC-1, all patientswere categorized into three groups: no/grade 1-2/grade 3-4 neutropenia. Five-year overall survival (OS) and disease-free survival (DFS) were compared between groups and subgroups stratified by IC regimen. We also explored the occurrence of IC-1–induced myelosuppression events and the minimal value of post-treatment neutrophil-to-lymphocyte ratio (post-NLR(min)). Univariate/multivariate analyses were performed to investigate the effect of IC-1–induced neutropenia, timing of neutropenia, number of myelosuppression events, and high post-NLR(min) on OS/DFS. RESULTS: Grade 1-2/grade 3-4 neutropeniawere associatedwith poorer OS/DFS than no neutropenia (all p < 0.05); OS/DFS were not significantly different between patients experiencing grade 1-2 vs. 3-4 neutropenia. Neutropenia had no significant effect on OS/DFS in patients receiving docetaxel–cisplatin–5-fluorouracil (TPF). Grade 1-2 (grade 3-4) neutropenia negatively influenced OS/DFS in patients receiving cisplatin–5-fluorouracil (PF) (PF and docetaxel–cisplatin [TP]; all p < 0.05). Neutropenia, two/three myelosuppression events, and high post-NLR(min) (≥ 1.33) was most frequent on days 5-10, second and third week of IC-1, respectively. After adjustment for covariates, IC-1–induced neutropenia, two/three myelosuppression events, and post-NLR(min) ≥ 1.33were validated as negative predictors of OS/DFS (all p < 0.05); timing of neutropenia had no significant effect. CONCLUSION: Occurrence of neutropenia, number of myelosuppression events, and high post-NLR(min) during PF/TP IC-1 have prognostic value for poor survival in LANPC. |
format | Online Article Text |
id | pubmed-6056978 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Korean Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-60569782018-07-27 Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area Xu, Cheng Yang, Shi-Ping Zhang, Yuan Tang, Ling-Long Zhou, Guan-Qun Liu, Xu Mao, Yan-Ping Guo, Rui Li, Wen-Fei Chen, Lei Lin, Ai-Hua Sun, Ying Ma, Jun Cancer Res Treat Original Article PURPOSE: The purpose of this study was to investigate the effect of neutropenia during the first cycle of induction chemotherapy (IC-1) on survival in locoregionally advanced nasopharyngeal carcinoma (LANPC). MATERIALS AND METHODS: Eligible patients (n=545) with LANPC receiving IC+concurrent chemoradiotherapy were included. Based on nadir neutrophil afterIC-1, all patientswere categorized into three groups: no/grade 1-2/grade 3-4 neutropenia. Five-year overall survival (OS) and disease-free survival (DFS) were compared between groups and subgroups stratified by IC regimen. We also explored the occurrence of IC-1–induced myelosuppression events and the minimal value of post-treatment neutrophil-to-lymphocyte ratio (post-NLR(min)). Univariate/multivariate analyses were performed to investigate the effect of IC-1–induced neutropenia, timing of neutropenia, number of myelosuppression events, and high post-NLR(min) on OS/DFS. RESULTS: Grade 1-2/grade 3-4 neutropeniawere associatedwith poorer OS/DFS than no neutropenia (all p < 0.05); OS/DFS were not significantly different between patients experiencing grade 1-2 vs. 3-4 neutropenia. Neutropenia had no significant effect on OS/DFS in patients receiving docetaxel–cisplatin–5-fluorouracil (TPF). Grade 1-2 (grade 3-4) neutropenia negatively influenced OS/DFS in patients receiving cisplatin–5-fluorouracil (PF) (PF and docetaxel–cisplatin [TP]; all p < 0.05). Neutropenia, two/three myelosuppression events, and high post-NLR(min) (≥ 1.33) was most frequent on days 5-10, second and third week of IC-1, respectively. After adjustment for covariates, IC-1–induced neutropenia, two/three myelosuppression events, and post-NLR(min) ≥ 1.33were validated as negative predictors of OS/DFS (all p < 0.05); timing of neutropenia had no significant effect. CONCLUSION: Occurrence of neutropenia, number of myelosuppression events, and high post-NLR(min) during PF/TP IC-1 have prognostic value for poor survival in LANPC. Korean Cancer Association 2018-07 2017-07-24 /pmc/articles/PMC6056978/ /pubmed/28745036 http://dx.doi.org/10.4143/crt.2017.255 Text en Copyright © 2018 by the Korean Cancer Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Xu, Cheng Yang, Shi-Ping Zhang, Yuan Tang, Ling-Long Zhou, Guan-Qun Liu, Xu Mao, Yan-Ping Guo, Rui Li, Wen-Fei Chen, Lei Lin, Ai-Hua Sun, Ying Ma, Jun Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area |
title | Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area |
title_full | Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area |
title_fullStr | Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area |
title_full_unstemmed | Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area |
title_short | Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area |
title_sort | neutropenia during the first cycle of induction chemotherapy is prognostic for poor survival in locoregionally advanced nasopharyngeal carcinoma: a real-world study in an endemic area |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056978/ https://www.ncbi.nlm.nih.gov/pubmed/28745036 http://dx.doi.org/10.4143/crt.2017.255 |
work_keys_str_mv | AT xucheng neutropeniaduringthefirstcycleofinductionchemotherapyisprognosticforpoorsurvivalinlocoregionallyadvancednasopharyngealcarcinomaarealworldstudyinanendemicarea AT yangshiping neutropeniaduringthefirstcycleofinductionchemotherapyisprognosticforpoorsurvivalinlocoregionallyadvancednasopharyngealcarcinomaarealworldstudyinanendemicarea AT zhangyuan neutropeniaduringthefirstcycleofinductionchemotherapyisprognosticforpoorsurvivalinlocoregionallyadvancednasopharyngealcarcinomaarealworldstudyinanendemicarea AT tanglinglong neutropeniaduringthefirstcycleofinductionchemotherapyisprognosticforpoorsurvivalinlocoregionallyadvancednasopharyngealcarcinomaarealworldstudyinanendemicarea AT zhouguanqun neutropeniaduringthefirstcycleofinductionchemotherapyisprognosticforpoorsurvivalinlocoregionallyadvancednasopharyngealcarcinomaarealworldstudyinanendemicarea AT liuxu neutropeniaduringthefirstcycleofinductionchemotherapyisprognosticforpoorsurvivalinlocoregionallyadvancednasopharyngealcarcinomaarealworldstudyinanendemicarea AT maoyanping neutropeniaduringthefirstcycleofinductionchemotherapyisprognosticforpoorsurvivalinlocoregionallyadvancednasopharyngealcarcinomaarealworldstudyinanendemicarea AT guorui neutropeniaduringthefirstcycleofinductionchemotherapyisprognosticforpoorsurvivalinlocoregionallyadvancednasopharyngealcarcinomaarealworldstudyinanendemicarea AT liwenfei neutropeniaduringthefirstcycleofinductionchemotherapyisprognosticforpoorsurvivalinlocoregionallyadvancednasopharyngealcarcinomaarealworldstudyinanendemicarea AT chenlei neutropeniaduringthefirstcycleofinductionchemotherapyisprognosticforpoorsurvivalinlocoregionallyadvancednasopharyngealcarcinomaarealworldstudyinanendemicarea AT linaihua neutropeniaduringthefirstcycleofinductionchemotherapyisprognosticforpoorsurvivalinlocoregionallyadvancednasopharyngealcarcinomaarealworldstudyinanendemicarea AT sunying neutropeniaduringthefirstcycleofinductionchemotherapyisprognosticforpoorsurvivalinlocoregionallyadvancednasopharyngealcarcinomaarealworldstudyinanendemicarea AT majun neutropeniaduringthefirstcycleofinductionchemotherapyisprognosticforpoorsurvivalinlocoregionallyadvancednasopharyngealcarcinomaarealworldstudyinanendemicarea |